San Antonio researcher makes Hepatitis C breakthrough drug 90 percent cure rate reported; no side effects reported after taking Sofosbuvir
Author: Jessie Degollado, Reporter, jdegollado@ksat.com
Published On: May 23 2013 05:43:25 PM CDT Updated On: May 23 2013 05:44:46 PM CDT
Continue reading here.....
Related:
(May 21) European Medicines Agency Validates Gilead's Marketing Application for Sofosbuvir for the Treatment of Hepatitis C
(On April 08) Gilead Submitted New Drug Application to U.S. FDA for Sofosbuvir (GS-7977) for the Treatment of Hepatitis C
A New Era in the Management of Chronic Hepatitis C
Discusses interferon free therapies, a must see video presented by Harvard Medical School
Click here to view video......
May 16
Current and Future Therapies for Hepatitis C Virus Infection, from NIH
May 2
Gilead Sofosbuvir and ledipasvir: Plans to initiate a third Phase 3 clinical trial with and without ribavirin
April
EASL: Treatment With Sofosbuvir + Ribavirin for 12 Weeks Achieves SVR12 of 78% in GT 2/3 Interferon-Ineligible, -Intolerant, or -Unwilling Patients: Results of the Phase 3 POSITRON Trial -
EASL: Phase 3 Randomized Controlled Trial of All-Oral Treatment With Sofosbuvir + Ribavirin for 12 Weeks Compared to 24 Weeks of PEG + Ribavirin in Treatment-Naïve GT 2/3 HCV-Infected Patients (FISSION)
EASL: All Oral Therapy With Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment-Experienced Genotype 2/3 HCV-Infected Patients: Results of the Phase 3 FUSION Trial
Summary from EASL 2013 for Hepatitis C - New HCV DAAs on their way soon: what do the phase III studies tell us?
The New England Journal Of Medicine (NEJM)
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
I.M. Jacobson and Others
Published Online: April 23, 2013
*Free Abstract
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
E. Lawitz and Others
Published Online: April 23, 2013
*Free Abstract
No comments:
Post a Comment